Stock events for Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics' stock price has been impacted by positive clinical data from the DELIVER trial, Breakthrough Therapy Designations for z-rostudirsen and DYNE-101, and a public offering that raised approximately $230.0 million. The company reported a cash position of $791.9 million in Q3 2025 and $1.1 billion in Q4 2025, which is expected to fund operations into Q1 2028. Dyne plans to submit a BLA for U.S. Accelerated Approval of z-rostudirsen in Q2 2026, with a potential U.S. launch targeted for Q1 2027. The stock has experienced volatility, with a 52-week range fluctuating between $6.36 and $25.00, and has shown an increase of 10.81% over the last six months.
Demand Seasonality affecting Dyne Therapeutics, Inc.’s stock price
The demand for Dyne Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the prevalence of the targeted diseases and the progress and success of its clinical trials and regulatory approvals.
Overview of Dyne Therapeutics, Inc.’s business
Dyne Therapeutics is a clinical-stage biotechnology company focused on developing therapies for genetically driven neuromuscular diseases, utilizing its FORCE™ platform to deliver therapeutic oligonucleotides directly to muscle tissue. The company's pipeline includes DYNE-101 for Myotonic Dystrophy Type 1 (DM1), DYNE-251 for Duchenne Muscular Dystrophy (DMD), and DYNE-302 for Facioscapulohumeral Dystrophy (FSHD). Dyne Therapeutics plans to expand its portfolio to include treatments for other rare skeletal muscle, cardiac, and metabolic muscle diseases.
DYN’s Geographic footprint
Dyne Therapeutics is headquartered in Waltham, Massachusetts, United States, and conducts global clinical trials, such as the ACHIEVE trial for DM1 and the DELIVER trial for DMD. DYNE-101 has received Orphan Drug Designation in Japan, indicating an international reach. The majority of its shareholders are from the United States (88.4%), with smaller percentages from the United Kingdom, Netherlands, and Canada.
DYN Corporate Image Assessment
Dyne Therapeutics' brand reputation has been positively influenced by clinical and regulatory milestones, including positive topline results from the DELIVER trial and Breakthrough Therapy Designations from the FDA. The Orphan Drug Designation in Japan for DYNE-101 also contributes to a positive perception. Potential challenges include safety concerns with drug delivery systems, delayed progress in clinical trials, competition, internal instability, and shareholder dilution.
Ownership
Institutional investors hold over 90% of Dyne Therapeutics' shares, with major holders including Janus Henderson Group Plc, Vanguard Group Inc, and BlackRock, Inc. Individual insiders hold approximately 0.451% of the shares, with executives and directors holding about 2.47 million shares.
